Clinical Trials Logo

Diabetic Nephropathies clinical trials

View clinical trials related to Diabetic Nephropathies.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT01299246 Active, not recruiting - Diabetic Foot Clinical Trials

The Effectiveness of Improving Self-care After Counseling for the Diabetics Mellitus Foots Around Chiayi Region

Start date: November 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Objectives: Preventing diabetic foot problems (DFP) and associated consequences, such as amputation, is a critical in rural regions. The objective is to present on the association of non-invasive DFP assessment tools and physiological indicators for the early detection of DFP among rural cases of diabetes in Taiwan.

NCT ID: NCT01273675 Active, not recruiting - Clinical trials for Diabetic Nephropathy

An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy

Start date: September 2010
Phase: N/A
Study type: Observational

It is well understood that hypertension, dyslipidemia, and diabetes mellitus are the major risks of chronic kidney disease. Current guidelines recommend screening kidney estimated glomerular filtration function with serum creatinine. But it is not the utmost effective method and the GFR would be underestimated. Since good correlation was noticed between serum creatinine and chronic kidney disease, urinary microalbumin levels is better for patients with risks of chronic kidney diseases. With adequate and early education, or antihypertensive agents with angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB), all could alleviate renal function deterioration and the severity of proteinuria. As a result, high sensitive methods is urgent and needed for early screening and diseases following up under medication with ACEi and ARB in chronic kidney disease patients. In this project, the investigators are going to include the patients with typy II diabetes mellitus combining with hypertension who are treated with antihypertensive agents. Such volunteers will be treated with Candesartan 8-16mg/ day and maintain systolic blood pressure <130 mm/Hg, diastolic blood pressure < 80 mm/ Hg as the goal. Therefore, this project would make effort on correlation with urinary microalbumin and other biomarkers changes under Candesartan treatment- one of ARB medication for 12 weeks, and further exploration of new biomarkers that may be related to renal parenchymal injuries.

NCT ID: NCT00498147 Active, not recruiting - Clinical trials for Diabetic Retinopathy

Determining Rates of Cardiovascular Complications Among Patients of a Managed Diabetes Care Program

DECIDE
Start date: July 2007
Phase: N/A
Study type: Observational

The primary objective of this study is to identify whether cardiovascular complication rates are lower in patients who participate in managed diabetes care, in comparison to provincial and national rates. This study will involve an electronic medical record (EMR) chart audit, augmented by a manual review of hospital and other pertinent medical records, as necessary.